Work

Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.3013

Authors: Ryan J. Sullivan, David S. Hong, Anthony W. Tolcher, Amita Patnaik, Geoffrey Shapiro, Bartosz Chmielowski, Antoni Ribas, Les H. Brail, Jennifer Roberts, Lucy Lee, Brenda O'Connell, Jeffrey Lorne Kutok, Suresh Mahabhashyam, Claudio Dansky Ullmann, Michael A. Postow, Jedd D. Wolchok

Institutions: Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, South Texas Accelerated Research Therapeutics, Dana-Farber Cancer Institute, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, Los Angeles Medical Center, Infinity Pharmaceuticals (United States), Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2890904005

Cites:

Cited by: 59

Related to: 10